Mabwell-B (02493) Reports RMB 621 Million Revenue for First Three Quarters, Up 9.77% Year-on-Year

Stock News10-28

Mabwell-B (02493) announced its results for the first three quarters of 2026, reporting operating revenue of approximately RMB 621 million, up 9.77% year-on-year; net loss attributable to shareholders of the listed company was approximately RMB 678 million, with basic loss per share of RMB 1.6.

The company continues to deepen its global market commercialization layout. In the domestic market, pharmaceutical sales revenue for the third quarter of 2026 reached approximately RMB 123 million, up 122.13% year-on-year.

In overseas markets, in July 2026, the company separately entered into licensing agreements with partners in the Philippines, Vietnam, and Malaysia to jointly advance the local registration and commercialization of 9MW0813; in the same month, the company reached a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc., with both parties engaging in deep cooperation on the registration, production, and commercialization of 9MW0813 in the Gulf Arab states.

In August 2026, its wholly-owned subsidiary Taikang Biotech successfully passed the Brazilian National Health Surveillance Agency (ANVISA) GMP on-site inspection for two denosumab injection products, 9MW0311 (Mailishu®) and 9MW0321 (Maiweijian®), marking the second time Mabwell has obtained a GMP certificate issued by a PIC/S member state drug regulatory authority, following Jordan.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1198732206?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-28 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1198732206","market":"nz","top_or_hot":-1,"title":"Mabwell-B (02493) Reports RMB 621 Million Revenue for First Three Quarters, Up 9.77% Year-on-Year","media":"Stock News","content":"<p>Mabwell-B (02493) announced its results for the first three quarters of 2026, reporting operating revenue of approximately RMB 621 million, up 9.77% year-on-year; net loss attributable to shareholders of the listed company was approximately RMB 678 million, with basic loss per share of RMB 1.6.<br><br>The company continues to deepen its global market commercialization layout. In the domestic market, pharmaceutical sales revenue for the third quarter of 2026 reached approximately RMB 123 million, up 122.13% year-on-year.<br><br>In overseas markets, in July 2026, the company separately entered into licensing agreements with partners in the Philippines, Vietnam, and Malaysia to jointly advance the local registration and commercialization of 9MW0813; in the same month, the company reached a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc., with both parties engaging in deep cooperation on the registration, production, and commercialization of 9MW0813 in the Gulf Arab states.<br><br>In August 2026, its wholly-owned subsidiary Taikang Biotech successfully passed the Brazilian National Health Surveillance Agency (ANVISA) GMP on-site inspection for two denosumab injection products, 9MW0311 (Mailishu®) and 9MW0321 (Maiweijian®), marking the second time Mabwell has obtained a GMP certificate issued by a PIC/S member state drug regulatory authority, following Jordan.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mabwell-B (02493) Reports RMB 621 Million Revenue for First Three Quarters, Up 9.77% Year-on-Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMabwell-B (02493) Reports RMB 621 Million Revenue for First Three Quarters, Up 9.77% Year-on-Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-28 19:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mabwell-B (02493) announced its results for the first three quarters of 2026, reporting operating revenue of approximately RMB 621 million, up 9.77% year-on-year; net loss attributable to shareholders of the listed company was approximately RMB 678 million, with basic loss per share of RMB 1.6.<br><br>The company continues to deepen its global market commercialization layout. In the domestic market, pharmaceutical sales revenue for the third quarter of 2026 reached approximately RMB 123 million, up 122.13% year-on-year.<br><br>In overseas markets, in July 2026, the company separately entered into licensing agreements with partners in the Philippines, Vietnam, and Malaysia to jointly advance the local registration and commercialization of 9MW0813; in the same month, the company reached a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc., with both parties engaging in deep cooperation on the registration, production, and commercialization of 9MW0813 in the Gulf Arab states.<br><br>In August 2026, its wholly-owned subsidiary Taikang Biotech successfully passed the Brazilian National Health Surveillance Agency (ANVISA) GMP on-site inspection for two denosumab injection products, 9MW0311 (Mailishu®) and 9MW0321 (Maiweijian®), marking the second time Mabwell has obtained a GMP certificate issued by a PIC/S member state drug regulatory authority, following Jordan.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02493","symbol_name":"迈威生物-B","start_time":0,"source_url":"","article_id":"1198732206","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1198732206","pubTimestamp":1793186292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Mabwell-B (02493) announced its results for the first three quarters of 2026, reporting operating revenue of approximately RMB 621 million, up 9.77% year-on-year; net loss attributable to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02493":"迈威生物-B","BK1161":"生物科技"},"translate_title":"Mabwell-B(02493)前三季度营收6.21亿元人民币，同比增长9.77%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02493":1},"content_text":"Mabwell-B (02493) announced its results for the first three quarters of 2026, reporting operating revenue of approximately RMB 621 million, up 9.77% year-on-year; net loss attributable to shareholders of the listed company was approximately RMB 678 million, with basic loss per share of RMB 1.6.The company continues to deepen its global market commercialization layout. In the domestic market, pharmaceutical sales revenue for the third quarter of 2026 reached approximately RMB 123 million, up 122.13% year-on-year.In overseas markets, in July 2026, the company separately entered into licensing agreements with partners in the Philippines, Vietnam, and Malaysia to jointly advance the local registration and commercialization of 9MW0813; in the same month, the company reached a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc., with both parties engaging in deep cooperation on the registration, production, and commercialization of 9MW0813 in the Gulf Arab states.In August 2026, its wholly-owned subsidiary Taikang Biotech successfully passed the Brazilian National Health Surveillance Agency (ANVISA) GMP on-site inspection for two denosumab injection products, 9MW0311 (Mailishu®) and 9MW0321 (Maiweijian®), marking the second time Mabwell has obtained a GMP certificate issued by a PIC/S member state drug regulatory authority, following Jordan.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1198732206","isCrawlerRequest":true}